Clinical Trial Update: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Ifinatamab Deruxtecan to physician's choice in relapsed small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Ifinatamab Deruxtecan (Ifinatamab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Small Cell Lung Cancer | Phase 3 | Status: RECRUITING